amikacin
therapy
exacerbations
pseudomonas
aeruginosa
infections
patients
cystic
fibrosis
amikacin
new
semisynthetic
aminoglycoside
antibiotic
activity
pseudomonas
aeruginosa
used
treat
acute
exacerbations
chronic
pulmonary
infections
patients
cystic
fibrosis
patients
ranged
years
age
mucoid
p
aeruginosa
isolated
sputum
amikacin
dose
usually
mg
kg
every
eight
hours
increased
mg
kg
carbenicillin
added
selected
cases
depending
clinical
course
although
p
aeruginosa
eliminated
patients
sputum
except
two
cases
good
clinical
response
courses
significant
improvement
chest
x
ray
films
spirometry
arterial
oxygen
tension
documented
courses
one
instance
serum
creatinine
level
elevation
could
attributed
antibiotic
two
patients
showed
minimal
db
unilateral
high
frequency
hearing
loss
serial
audiograms
activity
many
gentamicin
resistant
strains
high
blood
levels
among
attractive
properties
amikacin
amikacin
clinically
effective
treating
pseudomonas
associated
pulmonary
infections
complicating
cystic
fibrosis
